CHICAGO, IL--(Marketwired - Sep 28, 2015) - Healthcare professionals are concerned about recent increases in tuberculosis (TB) cases across the US because individuals with weakened immune systems, such as from diabetes, are highly susceptible to infections and complications. UV light air purification, which has been proven as an effective hospital infection control technology because of its ability to inactivate tuberculosis and other airborne bacteria and viruses, is now available to consumers and small businesses from RxAir®, a division of UV Flu Technologies (OTCBB: UVFT).

"TB is spread through the air from one person to another," the Centers for Disease Control and Prevention (CDC) website states. "The TB bacteria enter the air when a person with TB disease of the lungs or throat coughs, sneezes, speaks, or sings. People nearby may breathe in these bacteria and become infected. Certain groups of people (such as people with weakened immune systems) are at very high risk of developing TB disease once infected with TB bacteria."

"When a person with active TB or other airborne infectious disease enters a room and even breathes, they contaminate the space regardless of any sanitization that already occurred," explained Wladyslaw Kowalski, PhD, PE, one of the foremost experts and authors on airborne infection control. "Other people in the room, even those entering after the infected individual has exited, are exposed to infection by the simple act of breathing. Hospitals and healthcare facilities have been using industrial size UV light air purification systems for airborne infection control because they have been proven to inactivate a broad array of airborne viruses and bacteria, including TB."

The RxAir Air Purifier's patented kill chamber, which prolongs exposure to industrial-strength, high-intensity UV-C lights, and powerful air flow capacity continually inactivate airborne bacteria and viruses as they are produced, helping to prevent infection for everyone in the room. RxAir is one of the few UV light air purifiers for consumer and small business use that have been proven in independent EPA- and FDA-certified testing laboratories to destroy on first pass more than 99% of harmful viruses and bacteria. In addition to inactivating airborne bacteria that cause TB (even antibiotic resistant TB strains), RxAir's device disarms the airborne pathogens that cause MRSA (staph), strep (whooping cough), influenza, measles, pneumonia and a myriad of other antibiotic-resistant bacteria and viral infections.

According to the Mayo Clinic, the following diseases and medications are known to weaken one's immune system and defense against TB: diabetes, HIV/Aids; end-stage kidney disease; certain cancers; chemotherapy treatment; drugs to prevent rejection of transplanted organs; very young or advanced age; some drugs to prevent rheumatoid arthritis, Crohn's disease and psoriasis. The World Health Organization (WHO) notes that "People with diabetes have a 2-3 times higher risk of TB compared to people without diabetes."

"It is extremely important for people with weakened immune systems to minimize their exposure to TB and other harmful pathogens as much as possible," stated Bryan Stone, MD, Internal Medicine and Nephrology, Chief of Medicine for Desert Regional Medical Center. "UV light air purifiers, such as RxAir, are the best way to combat these airborne pathogens on a continuous basis. Many healthcare facilities trust this product. "

Dr. Stone added, "People can contract TB with inhalation of as few as one TB bacterium, which has helped it become widespread globally and one of the world's deadliest diseases. The increase in international travel hastens the spread of TB and lesser known, but dangerous, air-transmitted pathogens. RxAir gives everyone the best fighting chance to reduce their exposure to TB and harmful airborne transmitted pathogens that could cause severe complications or even death in those with weakened immune systems."

RxAir is available via RxAir.com and Amazon.com.

About RxAir
RxAir, a division of UV Flu Technologies Inc., promotes a healthy lifestyle through the use of its innovative patented, ViraTech air purification technology, thereby improving the quality of life of every customer. Independently tested by EPA- and FDA-certified laboratories, RxAir has been proven to destroy greater than 99% of bacteria and viruses and reduce concentrations of odors and VOCs. RxAir uses high-intensity germicidal UV lamps that destroy bacteria and viruses instead of just trapping them, setting it apart from ordinary air filtration units. RxAir® and ViraTech® are registered trademarks of UV Flu Technologies, Inc. For more information, visit RxAir.com or contact Michael Ross, CEO, UV Flu Technologies, 877-358-5455.

About Wladyslaw Kowalski, PhD, PE
 Dr. Kowalski is one of the world's foremost experts on hospital infection control, air cleaning design and construction and indoor air quality issues, including mold and bacterial contamination. Author of "Hospital Airborne Infection Control" and "Aerobiological Engineering Handbook," Dr. Kowalski designs air disinfection systems for hospitals and commercial buildings and speaks at international conferences on disease control and air cleaning. He is past chair of the Air Treatment Group of the International Ultraviolet Assoc. (IUVA) with whom he developed a series of guidelines for air treatment systems in collaboration with ASHRAE, ARI, and other professional societies. He is currently engaged in research on UV genomics and R&D for ultraviolet germicidal irradiation systems for hospital infection control.

About Bryan Stone, MD
 Dr. Bryan Stone combines his medical expertise as a board certified internal medicine and nephrology physician with a keen understanding of technology and an aptitude for invention to develop market-changing technologies. Dr. Stone is Desert Regional Medical Center's Chief of Medicine, Medical Director of Davita Cathedral City Dialysis Clinic, as well as Medical Application Specialist for Fluid Energy Conversion, a green energy company with patented disruptive technologies.